Riskpilot← Back to searchSign inGet full accessHemab ApS
APSActiveCVR 40837590Nordre Fasanvej 215Manufacture of pharmaceutical preparations · NACE 2120Est. 201932 employees
Revenue 2024
—
EBITDA margin
—
-77% vs 2023
Equity ratio
91.2%
Financial strength
Net profit 2024
DKK -48,2M
-112% vs 2023
| Revenue | — | — |
| EBITDA | DKK -47,9M | -77% |
| Net profit | DKK -48,2M | -112% |
| Total assets | DKK 96,9M | -31% |
| Equity | DKK 88,4M | -35% |
| Employees | 32 | — |
Legal name
Hemab ApS
CVR number
40837590
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
27. september 2019
Share capital
DKK 1.247.405
Employees
32 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et andet medlem af bestyrelsen, af bestyrelsesformanden i forening med et medlem af direktionen, af to medlemmer af direktionen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af produkter til brug for diagnosticering, behandling og/eller forebyggelse af hæmatologiske sygdomme med risiko for øget blødning eller udvikling af blodpropper.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | — | — | — | — |
| Staff expenses | -180 | -0 | -17.655 | -4.316 | -10.663 |
| EBITDA | -10.256 | -41.156 | -161.480 | -27.069 | -47.897 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -10.256 | -41.156 | -161.480 | -27.069 | -47.897 |
| Net financials | -294 | 1.023 | 224 | 5.081 | 270 |
| Profit before tax | -10.550 | -40.134 | -161.256 | -21.988 | -47.627 |
| Tax | -2.410 | -4.971 | -4.849 | 795 | 585 |
| Net profit | -8.139 | -35.163 | -156.407 | -22.783 | -48.212 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 14.496 | 78.696 | 32.916 | 139.476 | 96.902 |
| Equity | 10.532 | 68.035 | 6.101 | 136.196 | 88.354 |
| Long-term debt | 3.353 | 0 | 0 | 167 | 1.974 |
| Short-term debt | 611 | 10.661 | 26.815 | 3.113 | 6.574 |
| Total debt | 3.964 | 10.661 | 26.815 | 3.280 | 8.548 |
EBITDA margin
-4789700000.0%
This company
15.8%
Market median
-30314557062% vs market
20202024
Equity ratio
91.2%
This company
38.2%
Market median
+139% vs market
20202024
Return on equity
-54.6%
This company
18.4%
Market median
-397% vs market
20202024
Net profit margin
-4821200000.0%
This company
8.1%
Market median
-59520987754% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2019-09-27 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JH Management | Management | 2019 | — | — |
MN Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2019 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2026 | |
| Individual | 5.0% | 5.0% | 2023 | |
| Individual | 5.0% | 5.0% | 2025 | |
Novo Holdings A/S | Company | 15.0% | 15.0% | 2025 |
| Individual | 5.0% | 5.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2023 | |
| Individual | 10.0% | 10.0% | 2025 | |
GV1 Holding ApS | Company | 5.0% | 5.0% | 2020 |
| Individual | 5.0% | 5.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Hemab ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Benny Sørensen | Chief Executive Officer | 0 companies |
| Johan Henrik Faber | Management | 0 companies |
| Mads Nikolaj Behrndt-Eriksen | Management | 0 companies |
| Jørgen Søberg Petersen | Chairman | 0 companies |
| Joseph Anderson | Board of Directors | 0 companies |
| Mårten Steen | Board of Directors | 0 companies |
| Linda Catharina Bain | Board of Directors | 0 companies |
| Daniel Becker | Board of Directors | 0 companies |
| Søren Erik Bjørn | Board of Directors | 0 companies |
| John Michael Maraganore | Chairman | 0 companies |
| Camilla Petrycer Hansen | Board of Directors | 0 companies |
| Akshay Krishnadas Vaishnaw | Board of Directors | 0 companies |
| Thomas Dal Stenfeldt Batchelor | Board of Directors | 0 companies |
| Laura Anne Tadvalkar | Board of Directors | 0 companies |
| Kim Stengaard Holmsted | Chairman | 0 companies |
| Hans Heugh Wandall | Chairman | 0 companies |
| Uya Chuluunbaatar | Board of Directors | 0 companies |